Ischemia Reperfusion Injury – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Ischemia Reperfusion Injury – Drugs In Development, 2024 report and make more profitable business decisions.
Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative stress. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation, and aging.
The Ischemia Reperfusion Injury drugs in development market research report provide comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Ischemia Reperfusion Injury | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 75 molecules, with 61 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Ischemia Reperfusion Injury therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Ischemia Reperfusion Injury pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Ischemia Reperfusion Injury treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Abfero Pharmaceuticals IncAlloksys Life Sciences BV
Amyndas Pharmaceuticals LLC
Anagenics Ltd
Argenx SE
Asta Pharmaceuticals Co Ltd
Axolo Pharma Inc
Balmes Transplantation SAS
Beijing Northland Biotech Co Ltd
Bilix Co Ltd
Biogen Inc
Bolder Biotechnology Inc
Celdara Medical LLC
Cellvie Inc
CFM Pharma Holding BV
Chengdu Medical College
Corline Biomedical AB
Cypralis Ltd
Domainex Ltd
EVAS Therapeutics LLC
Faron Pharmaceuticals Oy
Flanders Institute for Biotechnology
French National Institute of Health and Medical Research
Gero LLC
Gifu University School of Medicine
Gilead Sciences Inc
Glucox Biotech AB
Glycan Therapeutics Inc
Ischemix Inc
Kansas State University
Kyoto Pharmaceutical University
Larix Bioscience LLC
Lee's Pharmaceutical Holdings Ltd
Lepton Pharmaceuticals Ltd
LUCA Science Inc
Mallinckrodt Plc
Marshall University
Monash University
Neuroene Therapeutics LLC
New Beta Innovation Ltd
New Horizons Pharma Inc
Nour Heart Therapeutics LLC
NuNerve Pty Ltd
Omeros Corp
Orion Corp
Oxitope Pharma BV
Pharmadrug Inc
PharmaTher Holdings Ltd
Pharming Group NV
Purine Pharmaceuticals Inc
Radikal Therapeutics Inc
Revive Therapeutics Ltd
Sairiyo Therapeutics Inc
SBI Pharmaceuticals Co Ltd
Slate Bio Inc
Stanford University
Stealth BioTherapeutics Inc.
The Hospital for Sick Children
TheraSource LLC
United Therapeutics Corp
University of Exeter
University of Illinois at Chicago
University of Iowa
University of Toledo
University of Western Australia
Young Therapeutics LLC
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Ischemia Reperfusion Injury reports